Latest News

Mutations Matter: Cholangiocarcinoma Tumor Profiling Awareness

At least half of patients with cholangiocarcinoma have mutations in their tumors that may be treatable with targeted drugs or immunotherapies that are either experimental or approved for other cancer types. These are available through clinical trials. Yet when surveyed, half of patients with this diagnosis said their tumor tissue hadn’t undergone molecular profiling to […]

Read More

Cancer Conferences Participation. June 2019

Between the 24th and 28th of June, Oncologica will participate in two relevant Cancer Conferences to be held in Cyprus. The 36th International Conference on the Advances in the Applications of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells. Date: June 24-26, 2019. Venue: Grecian Park Hotel, Konnos Bay, Cyprus One of […]

Read More

FDA Approves First Immunotherapy for Breast Cancer

Atezolizumab for Triple-Negative Disease Nick Mulcahy March 08, 2019 The US Food and Drug Administration today granted accelerated approval to atezolizumab (Tecentriq, Genentech/Roche) plus the chemotherapy nab-paclitaxel (Abraxane, Celgene) for the first-line treatment of unresectable locally advanced or metastatic, PD-L1-positive triple-negative breast cancer (TNBC). Atezolizumab is the first immunotherapy to be approved for breast cancer. […]

Read More

Genomics and cancer treatment: new events will showcase developments

The government hopes genome sequencing technology will improve the treatment of cancer A series of NHS and healthcare events are taking place over the coming weeks to spark a conversation among healthcare professionals about genomics. They will help educate healthcare professionals about the benefits of genomics – the practice of using people’s DNA and genetic […]

Read More

Oncofocus Cancer Test is now covered by all leading health insurers

Following signature of an agreement between Oncologica UK Ltd and another UK private medical insurer, all the leading UK health insurers’ customers now have access to the Oncofocus Cancer Test. The Oncofocus Cancer Test is the world’s most comprehensive genomic profiling platform test that enables oncologists to select precisely the most effective targeted therapies and […]

Read More

Prof U. Tirelli: The best cure against cancer is a test

Analysis of genetic mutations in cancer cells can be used to identify precisely the correct targeted therapies for patients. This information is therefore of crucial importance in choosing the correct therapeutic approach for each type of cancer. Oncologists today have limited information with regard to the biological characteristics of a tumour which can be used […]

Read More

4th Quality & Innovation Meeting – Pancreatic Disorders

Another important date for the fight to Pancreas Disorders. Today, Oncologica will participate at the 4th “Quality & Innovation Meeting” focused on Pancreatic Disorders, that will take place in the Ospedale San Raffaele (Milan). Leading international experts in the medical community will discuss the most relevant innovations in Pancreatic Cancer, including aspects of precision oncology […]

Read More

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Background: In order to facilitate implementation of precision medicine in clinical management of cancer, there is a need to harmonise and standardise the reporting and interpretation of clinically relevant genomics data. Methods: The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to propose a […]

Read More

Inter-rater reliability of programmed death ligand 1 (PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in Non-Small-Cell-Lung Cancer (NSCLC)

This year’s Nobel Prize in Physiology or Medicine for discoveries relating to the harnessing of the immune system in the treatment of cancer has highlighted the great benefits of this approach to therapy. Multiple immunotherapies targeting the immune checkpoint programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) pathway are now approved for the treatment of patients […]

Read More

Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs

The impact of precision oncology on guiding treatment decisions of late-stage cancer patients was previously studied in a retrospective analysis. However, the overall survival and costs were not previously evaluated. We report the overall survival and healthcare costs associated with precision oncology in these patients with advanced cancer. Building on a matched cohort study of 44 patients with metastatic […]

Read More

Nobel prize for medicine goes to cancer therapy

Two scientists who discovered how to fight cancer using the body’s immune system have won the 2018 Nobel Prize for physiology or medicine. The work, by Professor James P Allison from the US and Professor Tasuku Honjo from Japan, has led to treatments for advanced, deadly skin cancer. Immune checkpoint therapy has revolutionised cancer treatment, said […]

Read More

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

Oncologica contributes to a seminal study by Paul Scorer, in partnership with colleagues in the IMED Biotech Unit at AstraZeneca, who have investigated the consistency of tumour and immune cell programmed cell death ligand-1 expression, within and between tumour blocks, using the VENTANA SP263 assay. Several anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 […]

Read More